Relapsed and refractory Diffuse Large B Cell Lymphoma (rrDLBCL) presents a significant challenge in hematology-oncology, with approximately 30-40% of DLBCL patients experiencing relapse or resistance to treatment. This underscores the urgent need to better understand the molecular mechanisms governing therapeutic resistance. Signal Transducer and Activator of Transcription 6 (STAT6) has been previously identified as a gene with recurrent D419 gain-of-function mutations in rrDLCBL. When STAT6D419mutations are present in DLBCL tumour cells, we have demonstrated that transcription of the chemokine CCL17 (aka TARC) is increased, and tumours have increased infiltration of CD4+ T cells. However, the significance of increased T cell infiltration had not been determined. In the present study, we developed a mouse model of STAT6D419Nmutant DLBCL, that recapitulates the critical features of human STAT6D419mutant DLBCL, including increased expression of phospho-STAT6, increased CD4+ T cell invasion, and resistance to doxorubicin treatment. With this model, we found CD4+ T cells in STAT6D419Ntumours have higher expression of the receptor for CCL17, CCR4. Usingex vivofunctional assays we demonstrate that STAT6D419Ntumour cells are directly chemoattractive to CCR4+ CD4+ T cells, and when CCR4 is inhibited using a small molecule antagonist, CD4+ T cells in STAT6D419Ntumours are reduced and STAT6D419Ntumours regain therapeutic sensitivity to doxorubicin. Using PhenoCycler imaging of human rrDLBCL samples, we find that STAT6D419tumours indeed have increased expression of phospho-STAT6+ and increased cellular interactions between phospho-STAT6+ tumour cells and CD4+/ CCR4+ CD4+ T cells. Thus, our data identify CCR4 as an attractive therapeutic target in STAT6D419mutant rrDLBCL.